1. Home
  2. MLYS vs STKL Comparison

MLYS vs STKL Comparison

Compare MLYS & STKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • STKL
  • Stock Information
  • Founded
  • MLYS 2019
  • STKL 1973
  • Country
  • MLYS United States
  • STKL United States
  • Employees
  • MLYS N/A
  • STKL N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • STKL Precious Metals
  • Sector
  • MLYS Health Care
  • STKL Basic Materials
  • Exchange
  • MLYS Nasdaq
  • STKL Nasdaq
  • Market Cap
  • MLYS 890.6M
  • STKL 730.4M
  • IPO Year
  • MLYS 2023
  • STKL N/A
  • Fundamental
  • Price
  • MLYS $37.16
  • STKL $6.39
  • Analyst Decision
  • MLYS Strong Buy
  • STKL Strong Buy
  • Analyst Count
  • MLYS 6
  • STKL 2
  • Target Price
  • MLYS $42.60
  • STKL $9.50
  • AVG Volume (30 Days)
  • MLYS 2.6M
  • STKL 531.9K
  • Earning Date
  • MLYS 11-10-2025
  • STKL 11-04-2025
  • Dividend Yield
  • MLYS N/A
  • STKL N/A
  • EPS Growth
  • MLYS N/A
  • STKL N/A
  • EPS
  • MLYS N/A
  • STKL N/A
  • Revenue
  • MLYS N/A
  • STKL $762,882,000.00
  • Revenue This Year
  • MLYS N/A
  • STKL $12.80
  • Revenue Next Year
  • MLYS N/A
  • STKL $7.91
  • P/E Ratio
  • MLYS N/A
  • STKL N/A
  • Revenue Growth
  • MLYS N/A
  • STKL 11.44
  • 52 Week Low
  • MLYS $8.24
  • STKL $3.65
  • 52 Week High
  • MLYS $39.20
  • STKL $8.11
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 86.84
  • STKL 53.44
  • Support Level
  • MLYS $35.00
  • STKL $6.21
  • Resistance Level
  • MLYS $15.79
  • STKL $6.67
  • Average True Range (ATR)
  • MLYS 2.50
  • STKL 0.20
  • MACD
  • MLYS 2.05
  • STKL -0.00
  • Stochastic Oscillator
  • MLYS 91.73
  • STKL 55.56

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About STKL SunOpta Inc.

SunOpta Inc is a Canadian company that focuses on a healthy product portfolio. The company is a manufacturer for natural and private label brands and also produces its own propriety brands, including SOWN, Dream and West Life. The core of its product portfolio is a range of plant-based beverages, including oat, almond, soy, coconut and rice milks and creamers, which have a favorable climate profile relative to traditional dairy milks in terms of lower carbon emissions and water usage. Their plant-based offerings include non-genetically modified, organic, and gluten-free products. The consumer products portfolio also includes protein shakes, teas, broths, and fruit snacks. Geographically, the company operates in U.S, Canada and Others, out of which it derives maximum revenue from U.S.

Share on Social Networks: